Breast-conserving surgery versus mastectomy for older women with triple-negative breast cancer: population-based study
Publication: Journal of Comparative Effectiveness Research
Abstract
Purpose: To assess whether the poor prognosis of triple-negative breast cancer (TNBC) necessitates a more aggressive surgical approach. Methods: We examined the association of: breast-conserving surgery (BCS); BCS plus radiotherapy; mastectomy; and mastectomy plus radiotherapy with overall and breast cancer-specific survival of stage I–III TNBC patients aged 66 years and older. We used unweighted and inverse probability of treatment weighted Cox proportional hazards regression and the Fine and Gray sub-distribution model. Results: Among 4333 women, individuals who were selected for BCS, mastectomy or mastectomy plus radiotherapy had lower adjusted overall and breast cancer-specific survival compared with women who had BCS plus radiotherapy. Conclusion: In this population-based study, women with TNBC treated with BCS plus radiotherapy have a better prognosis than those treated with BCS, mastectomy or mastectomy plus radiotherapy. Given the poor prognosis of TNBC and selection bias inherent in observational studies, these findings should be confirmed in further studies such as randomized clinical trials.
Supplementary Material
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Metzger-Filho O, Sun Z, Viale G et al. Patterns of recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX. J. Clin. Oncol. 31(25), 3083–3090 (2013).
2.
Russnes HG, Lingjaerde OC, Borresen-Dale AL, Caldas C. Breast cancer molecular stratification: from intrinsic subtypes to integrative clusters. Am. J. Pathol. 187(10), 2152–2162 (2017).
3.
Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N. Engl. J. Med. 363(20), 1938–1948 (2010).
•• Review of the molecular characteristics and treatment of triple-negative breast cancer.
4.
Plasilova ML, Hayse B, Killelea BK, Horowitz NR, Chagpar AB, Lannin DR. Features of triple-negative breast cancer: analysis of 38,813 cases from the national cancer database. Medicine 95(35), e4614 (2016).
5.
Warburton R, Chiu CG, Roberts A et al. Current surgical management of breast cancer. Br. Columbia Med. J. 60, 92–98 (2018).
6.
National Comprehensive Cancer Network. NCCN Guidelines. www.nccn.org/professionals/physician_gls/default.aspx
7.
Lichter AS, Lippman ME, Danforth DN Jr et al. Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute. J. Clin. Oncol. 10(6), 976–983 (1992).
8.
Veronesi U, Cascinelli N, Mariani L et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N. Engl. J. Med. 347(16), 1227–1232 (2002).
9.
Fisher B, Anderson S, Bryant J et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N. Engl. J. Med. 347(16), 1233–1241 (2002).
10.
Chen Q-X, Wang X-X, Lin P-Y et al. The different outcomes between breast-conserving surgery and mastectomy in triple-negative breast cancer: a population-based study from the SEER 18 database. Oncotarget 8(3), 4773–4780 (2016).
• Population-based study showing that patients treated with breast-conserving surgery followed by radiotherapy had better outcomes than patients treated with mastectomy.
11.
Wang SE, Sun YD, Zhao SJ, Wei F, Yang G. Breast conserving surgery (BCS) with adjuvant radiation therapy showed improved prognosis compared with mastectomy for early staged triple negative breast cancer patients. Math. Biosci. Eng. 17(1), 92–104 (2019).
• Population-based study showing that patients treated with breast-conserving surgery followed by radiotherapy had better outcomes than patients treated with mastectomy or mastectomy and radiotherapy.
12.
Zhou J, Enewold L, Zahm SH et al. Breast conserving surgery versus mastectomy: the influence of comorbidities on choice of surgical operation in the Department of Defense health care system. Am. J. Surg. 206(3), 393–399 (2013).
13.
Abdulkarim BS, Cuartero J, Hanson J, Deschenes J, Lesniak D, Sabri S. Increased risk of locoregional recurrence for women with T1–2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J. Clin. Oncol. 29(21), 2852–2858 (2011).
14.
Adkins FC, Gonzalez-Angulo AM, Lei X et al. Triple-negative breast cancer is not a contraindication for breast conservation. Ann. Surg. Oncol. 18(11), 3164–3173 (2011).
15.
Zumsteg ZS, Morrow M, Arnold B et al. Breast-conserving therapy achieves locoregional outcomes comparable to mastectomy in women with T1–2N0 triple-negative breast cancer. Ann. Surg. Oncol. 20(11), 3469–3476 (2013).
16.
Parker CC, Ampil F, Burton G, Li BDL, Chu QD. Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer? Surgery 148(2), 386–391 (2010).
17.
Duggan MA, Anderson WF, Altekruse S, Penberthy L, Sherman ME. The Surveillance, Epidemiology, and End Results (SEER) program and pathology: toward strengthening the critical relationship. Am. J. Surg. Pathol. 40(12), e94–e102 (2016).
18.
Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER–Medicare data: content, research applications, and generalizability to the United States elderly population. Med. Care 40(Suppl. 8), IV-3-18 (2002).
19.
National Cancer Institute. Comorbidity SAS Macro (2014 version). https://healthcaredelivery.cancer.gov/seermedicare/considerations/macro-2014.html
20.
Dieguez G, Ferro C, Rotter D. The cost burden of blood cancer care. A longitudinal analysis of commercially insured patients diagnosed with blood cancer (2018). www.lls.org/sites/default/files/Milliman%20study%20cost%20burden%20of%20blood%20cancer%20care.pdf
21.
Gibson DC, Chou L-N, Raji MA, Baillargeon JG, Kuo Y-F. Opioid prescribing trends in women following mastectomy or breast-conserving surgery before and after the 2014 federal reclassification of hydrocodone. Oncologist 25(4), 281–289 (2020).
22.
Killelea BK, Long JB, Chagpar AB et al. Trends and clinical implications of preoperative breast MRI in Medicare beneficiaries with breast cancer. Breast Cancer Res. Treat. 141(1), 155–163 (2013).
23.
Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat. Med. 34(28), 3661–3679 (2015).
24.
Cole SR, Hernán MA. Constructing inverse probability weights for marginal structural models. Am. J. Epidemiol. 168(6), 656–664 (2008).
25.
Xu S, Ross C, Raebel MA, Shetterly S, Blanchette C, Smith D. Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals. Value Health 13(2), 273–277 (2010).
26.
Pezzi A, Cavo M, Biggeri A, Zamagni E, Nanni O. Inverse probability weighting to estimate causal effect of a singular phase in a multiphase randomized clinical trial for multiple myeloma. BMC Med. Res. Methodol. 16(1), 150 (2016).
27.
Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J. Am. Stat. Assoc. 94(446), 496–509 (1999).
28.
Bolch CA, Chu H, Jarosek S, Cole SR, Elliott S, Virnig B. Inverse probability of treatment-weighted competing risks analysis: an application on long-term risk of urinary adverse events after prostate cancer treatments. BMC Med. Res. Methodol. 17(1), 93 (2017).
29.
National Cancer Institute. SEER–Medicare data use agreement (DUA). https://healthcaredelivery.cancer.gov/seermedicare/obtain/seerdua.pdf
30.
Houssami N, Macaskill P, Marinovich ML et al. Meta-analysis of the impact of surgical margins on local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy. Eur J Cancer 46(18), 3219–3232 (2010).
31.
Schoppmann SF, Bayer G, Aumayr K et al. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg. 240, 306–312 (2004).
32.
Gu J, Groot G, Boden C, Busch A, Holtslander L, Lim H. Review of factors influencing women’s choice of mastectomy versus breast conserving therapy in early stage breast cancer: a systematic review. Clin. Breast Cancer 18(4), e539–e554 (2018).
33.
Agarwal S, Pappas L, Neumayer L, Kokeny K, Agarwal J. Effect of breast conservation therapy vs mastectomy on disease-specific survival for early-stage breast cancer. JAMA Surg. 149(3), 267–274 (2014).
• Population-based study showing that patients with invasive breast cancer who received breast-conserving surgery and radiotherapy had better outcomes than those who received mastectomy or mastectomy and radiotherapy.
34.
Hwang ES, Lichtensztajn DY, Gomez SL, Fowble B, Clarke CA. Survival after lumpectomy and mastectomy for early stage invasive breast cancer: the effect of age and hormone receptor status. Cancer 119(7), 1402–1411 (2013).
35.
Van Maaren MC, De Munck L, De Bock GH et al. 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study. Lancet Oncol. 17(8), 1158–1170 (2016).
36.
Boniface JD, Szulkin R, Johansson ALV. Survival after breast conservation vs mastectomy adjusted for comorbidity and socioeconomic status: a Swedish national 6-year follow-up of 48,986 women. JAMA Surg. 156(7), 628–637 (2021).
• Recent large population-based study adjusted for comorbidities and socioeconomic factors. Found patients with invasive breast cancer treated with breast-conserving surgery had better outcomes than those treated with mastectomy alone or mastectomy and radiotherapy.
37.
Kim K, Park HJ, Shin KH et al. Breast conservation therapy versus mastectomy in patients with t1-2n1 triple-negative breast cancer: pooled analysis of KROG 14-18 and 14-23. Cancer Res. Treat. 50(4), 1316–1323 (2018).
38.
Noone A-M, Lund JL, Mariotto A et al. Comparison of SEER treatment data with Medicare claims. Med. Care 54(9), e55–e64 (2016).
39.
Vinh-Hung V, Verschraegen C. Breast-conserving surgery with or without radiotherapy: pooled-analysis for risks of ipsilateral breast tumor recurrence and mortality. J. Natl Cancer Inst. 96(2), 115–121 (2004).
40.
Longacre C, Neprash H, Shippee N, Tuttle T, Virnig B. Travel, treatment choice, and survival among breast cancer patients: a population-based analysis. Womens Health Rep. 2(1), 1–10 (2021).
41.
Guidolin K, Lock M, Vogt K et al. Recurrence and mortality after breast-conserving surgery without radiation. Curr. Oncol. 26(6), 380–388 (2019).
42.
Dragun AE, Huang B, Tucker TC, Spanos WJ. Disparities in the application of adjuvant radiotherapy after breast-conserving surgery for early stage breast cancer: impact on overall survival. Cancer 117(12), 2590–2598 (2011).
43.
Dreyer MS, Nattinger AB, Mcginley EL, Pezzin LE. Socioeconomic status and breast cancer treatment. Breast Cancer Res. Treat. 167(1), 1–8 (2018).
44.
Viani GA, Stefano EJ, Afonso SL et al. Breast-conserving surgery with or without radiotherapy in women with ductal carcinoma in situ: a meta-analysis of randomized trials. Radiat. Oncol. 2, 28 (2007).
45.
Pacheco JM, Gao F, Bumb C, Ellis MJ, Ma CX. Racial differences in outcomes of triple-negative breast cancer. Breast Cancer Res. Treat. 138(1), 281–289 (2013).
46.
Warner ET, Tamimi RM, Hughes ME et al. Racial and ethnic differences in breast cancer survival: mediating effect of tumor characteristics and sociodemographic and treatment factors. J. Clin. Oncol. 33(20), 2254–2261 (2015).
Information & Authors
Information
Published In
Pages: 953 - 967
PubMed: 35894095
Copyright
© 2022 Future Medicine Ltd.
History
Received: 2 November 2021
Accepted: 27 June 2022
Published online: 27 July 2022
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Breast-conserving surgery versus mastectomy for older women with triple-negative breast cancer: population-based study. (2022) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2021-0273
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Daniela Fulginiti, Sabrina S Domene, Carla Isabella Miret Durazo, Vanessa Boosahda, Thomas Campos Carmona, Karla Lora-Tavarez, Hrachya Ajamyan, Haya Al Shakkakee, Pallavi Shekhawat, Oxiris Yexalen Garcia Gonzalez, Breast-Conserving Surgery vs Mastectomy for Non-metastatic Breast Cancer: A Systematic Review and Meta-Analysis of Observational Studies, Cureus, 10.7759/cureus.88612, (2025).
- Buraq Ahmed, Qutaiba Al-Khames Aga, Kwok-Leung Cheung, Jana de Boniface, Michael Gnant, Maria-Joao Cardoso, Emad Rakha, Thiraviyam Elumalai, Nadia Harbeck, Orit Kaidar-Person, Amit Agrawal, Treatment strategies for triple-negative primary breast cancer in older women: a systematic review, JNCI Cancer Spectrum, 10.1093/jncics/pkaf049, 9, 3, (2025).
- Hsuan-Wen Lai, Yu-An Chen, Ka-Wai Tam, Surgical treatments for older breast cancer patients: A systematic review and meta-analysis of real-world evidence, Surgery, 10.1016/j.surg.2024.08.045, 176, 6, (1576-1590), (2024).
- Kiran K Rajan, Katherine Fairhurst, Beth Birkbeck, Shonnelly Novintan, Rebecca Wilson, Jelena Savović, Chris Holcombe, Shelley Potter, Overall survival after mastectomy versus breast-conserving surgery with adjuvant radiotherapy for early-stage breast cancer: meta-analysis , BJS Open, 10.1093/bjsopen/zrae040, 8, 3, (2024).
- Ottavia Amato, Valentina Guarneri, Fabio Girardi, Epidemiology trends and progress in breast cancer survival: earlier diagnosis, new therapeutics, Current Opinion in Oncology, 10.1097/CCO.0000000000000991, 35, 6, (612-619), (2023).
- Konstantinos Venetis, Elham Sajjadi, Mariia Ivanova, Silvia Andaloro, Simona Pessina, Chiara Zanetti, Alberto Ranghiero, Gabriele Citelli, Chiara Rossi, Marco Lucioni, Umberto Malapelle, Fabio Pagni, Massimo Barberis, Elena Guerini‐Rocco, Giuseppe Viale, Nicola Fusco, The molecular landscape of breast mucoepidermoid carcinoma, Cancer Medicine, 10.1002/cam4.5754, 12, 9, (10725-10737), (2023).